Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
BioMarin Pharmaceutical Inc. - Common Stock
(NQ:
BMRN
)
60.72
+0.73 (+1.22%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about BioMarin Pharmaceutical Inc. - Common Stock
< Previous
1
2
...
12
13
14
15
16
17
18
19
Next >
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
↗
October 31, 2022
Upgrades
Via
Benzinga
Mastercard To $428? Plus This Analyst Slashes PT On Intel
↗
October 31, 2022
Barclays cut the price target on Mastercard Incorporated (NYSE: MA) from $430 to $428. Barclays analyst Ramsey El-Assal maintained an Overweight rating on the stock. Mastercard shares fell 0.6% to...
Via
Benzinga
Why BioMarin Pharmaceuticals Fell 6.9% on Thursday
↗
October 27, 2022
Investors were expecting better top-line numbers from the company's earnings report.
Via
The Motley Fool
Expert Ratings for Biomarin Pharmaceutical
↗
October 13, 2022
Analysts have provided the following ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) within the last quarter:
Via
Benzinga
One Rejected BioMarin's Hemophilia Gene Therapy Goes Under FDA Review
↗
October 13, 2022
Via
Benzinga
Biomarin Pharmaceutical: Q3 Earnings Insights
↗
October 26, 2022
Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q3 earnings results on Wednesday, October 26, 2022 at 04:03 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Recap: Biomarin Pharmaceutical Q3 Earnings
↗
October 26, 2022
Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q3 earnings results on Wednesday, October 26, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
BioMarin Lays Off 4% Of Its Workforce To 'Simplify' The Company
↗
October 07, 2022
Via
Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
↗
September 15, 2022
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.
Via
Investor's Business Daily
BioMarin Says One Participant Diagnosed With Leukemia In Late-Stage Hemophilia Gene Therapy Trial
↗
September 12, 2022
Via
Benzinga
Expert Ratings for Biomarin Pharmaceutical
↗
August 04, 2022
Within the last quarter, Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings:
Via
Benzinga
BioMarin Lifts Annual Guidance On Better Than Expected Q2 Earnings
↗
August 04, 2022
Via
Benzinga
Analyst Ratings for Biomarin Pharmaceutical
↗
July 13, 2022
Within the last quarter, Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings:
Via
Benzinga
Neurocrine Leads 5 Stocks To Watch In Sickly Market
↗
September 03, 2022
Neurocrine Biosciences leads five medical stocks showing resilience.
Via
Investor's Business Daily
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
↗
August 24, 2022
Via
Benzinga
BioMarin Receives European Commission's Conditional Marketing Authorization For Gene Therapy Candidate
↗
August 24, 2022
The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ: BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the...
Via
Benzinga
Hopeful Golden Cross Forms On Biomarin Pharmaceutical's Chart
↗
August 09, 2022
If history is any guide, there may be good fortune ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be...
Via
Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
↗
August 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
7 Undervalued Biotech Stocks to Buy Before They Boom
↗
July 25, 2022
Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022
↗
July 13, 2022
Upgrades
Via
Benzinga
Pharma Rally Continues As Pfizer, Amgen Look To Break Out, Pulling Rivals With Them
↗
July 11, 2022
Four pharmaceutical stocks, including three biotech movers, are making big moves.
Via
Investor's Business Daily
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
↗
June 22, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
What 4 Analyst Ratings Have To Say About Biomarin Pharmaceutical
↗
June 13, 2022
Analysts have provided the following ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) within the last quarter:
Via
Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
↗
May 18, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More
↗
May 09, 2022
Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ:...
Via
Benzinga
BioMarin Achieves Record Q1 Sales Driven By Recently Approved Achondroplasia Therapy
↗
April 28, 2022
Via
Benzinga
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
↗
April 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Biomarin Pharmaceutical Earnings Preview
↗
April 26, 2022
Biomarin Pharmaceutical (NASDAQ:BMRN) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022
↗
April 25, 2022
Via
Benzinga
10 Biggest Price Target Changes For Monday
↗
April 25, 2022
Keybanc cut Salesforce, Inc. (NYSE: CRM) price target from $281 to $223. Salesforce shares fell 1.1% to $169.60 in pre-market trading.
Via
Benzinga
< Previous
1
2
...
12
13
14
15
16
17
18
19
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
